Psoromic Acid

Psoromic Acid

SCHEMBL2113679

COc1cc(C(=O)O)c2c(c1C)OC(=O)c1c(C)cc(O)c(C=O)c1O2

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.71
KDM4E B2RXH2 6/20 0.71
MEN1 O00255 6/20 0.71
ALDH1A1 P00352 6/20 0.71
KMT2A Q03164 6/20 0.71
TDP1 Q9NUW8 6/20 0.71
HPGD P15428 4/20 0.71
ALOX15 P16050 2/20 0.71
LMNA P02545 1/20 0.71
HSD17B10 Q99714 1/20 0.71
CYP3A4 P08684 6/20 0.53
ALOX12 P18054 2/20 0.53
PHPT1 Q9NRX4 2/20 0.53
CASP1 P29466 2/20 0.53
MED25 Q71SY5 1/20 0.53
SLCO1B3 Q9NPD5 1/20 0.53
SLCO1B1 Q9Y6L6 1/20 0.53
THRB P10828 3/20 0.53
RECQL P46063 3/20 0.53
USP2 O75604 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Psoromic Acid SCHEMBL29934794 1.00 MAPT (0.71) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL2111729 0.91 MEN1 (0.58) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL2114540 0.91 KDM4E (0.58) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL2112898 0.89 MEN1 (0.56) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL2114883 0.89 KDM4E (0.56) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL2112670 0.89 MEN1 (0.67) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL2112673 0.89 MEN1 (0.67) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL2112283 0.88 MAPT (0.61) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL2113411 0.88 KDM4E (0.56) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL2618036 0.88 MAPT (0.58) MAPTKDM4EMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140500-A1 HIGH THROUGHPUT METHODS, PROTEIN INHIBITORS, AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2020-05-07 US disclosed
US-20200138832-A1 COMPOUNDS AND PRODRUGS THEREOF FOR THE TREATMENT OF OPHTHALMIC DISEASE THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2020-05-07 US disclosed
EP-3482797-A1 INHIBITORS OF ALPHA-CRYSTALLIN AGGREGATION FOR THE TREATMENT FOR CATARACT The Regents Of The University Of Michigan (US) 2019-05-15 EP disclosed
EP-2874709-B1 INHIBITORS OF ALPHA-CRYSTALLIN AGGREGATION FOR THE TREATMENT FOR CATARACT UNIV MICHIGAN REGENTS (US) 2018-12-19 EP disclosed
US-9675623-B2 Non-surgical method of treatment for cataract THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-06-13 US disclosed
US-9675623-B2 Non-surgical method of treatment for cataract THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-06-13 US disclosed
US-20170020895-A1 Non-Surgical Method of Treatment for Cataract THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-01-26 US disclosed
US-20170020895-A1 Non-Surgical Method of Treatment for Cataract THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-01-26 US disclosed
US-20160220510-A1 ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-08-04 US disclosed
CN-105769850-A Application of psoromic acid in preparation of medicine for treating brain glioma and acute myeloid leukemia 苏州勤浩药物研究开发有限公司 2016-07-20 CN disclosed
US-20140031327-A1 NON-SURGICAL METHOD OF TREATMENT FOR CATARACT REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-01-30 US disclosed
CN-103127056-A Application of psoromic acid in anti-tumor drug preparation UNIV FUDAN 2013-06-05 CN disclosed
US-8158623-B2 Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2012-04-17 US disclosed
US-8158623-B2 Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2012-04-17 US disclosed
US-8158623-B2 Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2012-04-17 US disclosed
US-20100173905-A1 HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE 2010-07-08 US disclosed
US-20100173905-A1 HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE 2010-07-08 US disclosed
US-20100173905-A1 HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE 2010-07-08 US disclosed
EP-2199295-A1 COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2010-06-23 EP disclosed
EP-2199295-A1 COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2010-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200138832-A1 COMPOUNDS AND PRODRUGS THEREOF FOR THE TREATMENT OF OPHTHALMIC DISEASE CRYAB, CRYAA, CRYZ MAPT 103/4885KDM4E 4515/4885MEN1 3330/4885
US-20100173905-A1 HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME GPR119, CYP11B1, HSD11B1 MAPT 4246/4885KDM4E 4346/4885MEN1 730/4885
US-20160220510-A1 ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS AARS1, EPRS1, EEF1G MAPT 1595/4885KDM4E 1642/4885MEN1 4783/4885
US-20200140500-A1 HIGH THROUGHPUT METHODS, PROTEIN INHIBITORS, AND USES THEREOF HSF1, HSP90B1, HSPH1 MAPT 235/4885KDM4E 3318/4885MEN1 4407/4885
US-20140031327-A1 NON-SURGICAL METHOD OF TREATMENT FOR CATARACT CRYAB, CRYZ, CRYAA MAPT 125/4885KDM4E 4144/4885MEN1 4740/4885
US-20170020895-A1 Non-Surgical Method of Treatment for Cataract CRYAB, CRYZ, CRYAA MAPT 125/4885KDM4E 4144/4885MEN1 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.